Abstract
Background Epidemiological studies show increased cardiovascular disease (CVD) risks amongst individuals with psychiatric disorders, but to what degree this comorbidity is mediated by genetic and non-genetic (including medications) factors remains unclear. This study examined the genetic contribution to this comorbidity, and the sex-specific causal association between higher genetic risk of three psychiatric disorders [major depression (MD), schizophrenia and bipolar disorder] and three CVDs [coronary artery disease (CAD), heart failure (HF) and atrial fibrillation].
Methods Genetic correlation and polygenic overlap between psychiatric disorders and CVDs were estimated using summary statistics from genome-wide association studies. Association between polygenic scores (PGS) for psychiatric disorders and CVD outcomes was assessed in 345,340 European-ancestry individuals (UK Biobank) using logistic regression.
Results Though substantial genetic overlap was identified between psychiatric disorders and CVDs, a significant genetic correlation (rg ranged between 0.11 and 0.25, p < 7.8E-06) was only observed between MD and all three CVDs. A 1-standard-deviation increase in PGSMD was associated with a 1.11- (95% CI: 1.06 - 1.16; p = 4.9E-06) and 1.09-fold (95% CI: 1.04 - 1.14; p = 0.00041) higher risk of incident CAD and HF in females, but only with a 1.04-fold (95% CI: 1.02 - 1.07; p = 0.0019) increased risk of incident CAD in males. The PGSMD was associated with CAD and HF even in the absence of any psychiatric disorder diagnosis.
Conclusions Our results suggest that the increased CVD risk in individuals with schizophrenia and bipolar disorder is likely a consequence of non-genetic factors (such as lifetime hardships and medications). Notably, shared genetic risk is an important contributor to CVD comorbidity in individuals with a diagnosis or a higher risk of MD, and more so in females than in males.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JCJ is supported by a National Health and Medical Research Council (NHMRC) IDEAS grant (2000637). KS is supported by the American Heart Association Predoctoral Fellowship (AHA827137). LKD is supported by funding from the National Institute of Mental Health (NIMH) (R56MH120736); and the National Human Genome Research Institute (NHGRI) and the Office of Research on Women's Health (R01HG011405). NRW is supported by NHMRC Program Grant (1113400); and NHMRC Investigator Grant (1173790). SS is supported by funding from the NHMRC Program Grant (1113400); NHMRC Early Career Fellowship (APP1142495); and National Heart Foundation Future Leader Fellowship (105638).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Current study was conducted using the UK Biobank Resource under Application Number 12505. This research is covered by the University of Queensland Human Research Ethics Committee approval (HREC number 2020/HE002938). The VUMC Institutional Review Board oversees BioVU and approved this project (IRB#172020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript. Publicly available GWAS summary statistics analysed in this study are properly referenced in the manuscript. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data.
Non-Standard Abbreviations and Acronyms
- AF
- Atrial fibrillation
- AHA
- American Heart Association
- AUC
- Area under the receiver operator characteristic curve
- BD
- Bipolar disorder
- BMI
- Body mass index
- CAD
- Coronary artery disease
- CI
- Confidence interval
- CPT
- Current Procedural Terminology
- CVD
- Cardiovascular disease
- EHR
- Electronic health record
- GWAS
- Genome-wide association study
- HF
- Heart failure
- ICD
- International Classification of Diseases
- LD
- Linkage disequilibrium
- LDSC
- LD score regression
- MD
- Major depression
- MDD
- Major depressive disorder
- MHC
- Major histocompatibility complex
- MR
- Mendelian randomisation
- OR
- Odds ratio
- PC
- Principal component
- PGS
- Polygenic score
- PRS-CS
- Polygenic Risk Score–Continuous Shrinkage
- SCZ
- Schizophrenia
- SD
- Standard deviation
- SNP
- Single nucleotide polymorphism
- VUMC
- Vanderbilt University Medical Center